Clinical Trials on Hyperparathyroidism Tertiary in Australia
Total 21 results
-
KAI PharmaceuticalsNucleus Network LtdCompletedHyperparathyroidism, SecondaryAustralia
-
Medical University of ViennaUnknownPrimary Hyperparathyroidism | Bone MetabolismAustria
-
Medical University of ViennaNational Bank of AustriaCompletedPrimary Hyperparathyroidism | Osteoporosis | OsteopeniaAustria
-
KAI PharmaceuticalsCompletedHyperparathyroidism, SecondaryUnited States, Australia
-
AmgenCompletedHyperparathyroidism, Primary | HypercalcemiaUnited States, Canada, Russian Federation, Hungary, Australia, Portugal, Poland
-
AbbVie (prior sponsor, Abbott)Assign Data Management and Biostatistics GmbHCompletedSecondary Hyperparathyroidism | Chronic Kidney Disease Stage V | Cardiac MorbidityAustria
-
Region SkaneJagiellonian University; Sahlgrenska University Hospital, Sweden; Haukeland University... and other collaboratorsCompletedHypoparathyroidism PostproceduralNorway, Sweden, Austria, Poland
-
Rainer OberbauerAmgenCompletedSecondary Hyperparathyroidism | Left Ventricular Hypertrophy | Chronic Kidney Disease Requiring Chronic DialysisAustria
-
Medical University of ViennaCompletedSecondary Hyperparathyroidism | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | Kidney ReplacementAustria
-
Medical University of ViennaUnknownVitamin D Deficiency | Kidney Transplantation | Renal OsteodystrophyAustria
-
AbbVie (prior sponsor, Abbott)CompletedSecondary Hyperparathyroidism | Kidney InsufficiencyAustria, Germany
-
AmgenTerminatedHyperparathyroidism | Chronic Kidney Disease | Secondary Hyperparathyroidism | Hyperparathyroidism, Secondary | Kidney DiseaseUnited States, Belgium, Hungary, Spain, Australia, Germany, Poland, Mexico, Russian Federation, Slovakia
-
AmgenCompletedChronic Kidney Disease | Secondary HyperparathyroidismUnited States, Italy, Belgium, Denmark, Switzerland, Canada, Turkey, Spain, Austria, Germany, Hungary, Greece, France, Poland, Russian Federation, Czechia, Latvia, Lithuania, New Zealand, Portugal, Sweden, Estonia
-
AmgenCompletedHyperparathyroidism, SecondaryUnited States, Belgium, Italy, Switzerland, Canada, Turkey, Spain, Australia, Austria, Israel, Czechia, Hungary, Poland, France, Russian Federation, Germany, Denmark, Greece, Latvia, Lithuania, Netherlands, New Zealand, Portugal, Sweden
-
AmgenCompletedHyperparathyroidism, SecondaryUnited States, Belgium, Canada, France, Australia, Israel, Czechia, Hungary, Netherlands, Spain, Poland, Russian Federation, Italy, Sweden, Germany
-
AmgenCompletedHyperparathyroidism, SecondaryUnited States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Australia, Austria, Israel, Czechia, Hungary, Netherlands, Poland, France, Russian Federation, Sweden
-
AmgenCompletedHyperparathyroidism, SecondaryUnited States, Belgium, Italy, United Kingdom, Canada, Germany, Spain, Austria, Czechia, Hungary, France, Israel, Poland, Australia, Russian Federation
-
TakedaTakeda Development Center Americas, Inc.Active, not recruitingHypoparathyroidismUnited States, Spain, Denmark, Germany, Austria, Canada, Greece, Sweden, Italy, Norway, United Kingdom
-
Zynerba Pharmaceuticals, Inc.Completed22Q Deletion SyndromeUnited States, Australia
-
AmgenCompletedHyperparathyroidism | End Stage Renal Disease | Chronic Kidney Disease | Kidney Transplantation | Chronic Renal Failure | Hypophosphatemia | Kidney Disease | Chronic Allograft Nephropathy | Disordered Mineral Metabolism | Post Renal TransplantationUnited States, Canada, France, Italy, Belgium, Switzerland, Spain, Australia, Germany, Austria, Poland
-
Natera, Inc.Children's Hospital of Philadelphia; Montefiore Medical Center; University of... and other collaboratorsCompletedPrader-Willi Syndrome | DiGeorge Syndrome | 22q11 Deletion Syndrome | Angelman Syndrome | Trisomy 21 | Trisomy 18 | Trisomy 13 | Monosomy X | Sex Chromosome Abnormalities | 1p36 Deletion Syndrome | Cri-du-Chat SyndromeUnited States, Australia, Ireland, Spain, Sweden, United Kingdom